High Tech Pharm Co. Ltd (106190) - Cash Flow Conversion Efficiency
Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.60 Billion ≈ $4.47 Million USD) by net assets (₩126.99 Billion ≈ $86.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
High Tech Pharm Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how High Tech Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of High Tech Pharm Co. Ltd for a breakdown of total debt and financial obligations.
High Tech Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Waigaoqiao Free Trade Zone Group Co Ltd B
SHG:900912
|
0.022x |
|
DEFAMA Deutsche Fachmarkt AG
XETRA:DEF
|
0.065x |
|
Froch Enterprise Co Ltd
TW:2030
|
0.110x |
|
Garuda Maintenance Facility AeroAsia Tbk PT
JK:GMFI
|
-0.043x |
|
Orion Gold NL
JSE:ORN
|
-0.027x |
|
TerrAscend Corp
F:TED
|
0.028x |
|
Richmond Mutual Bancorporation Inc
NASDAQ:RMBI
|
0.024x |
|
Legacy Education Inc.
NYSE MKT:LGCY
|
0.023x |
Annual Cash Flow Conversion Efficiency for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of High Tech Pharm Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see High Tech Pharm Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩119.74 Billion ≈ $81.14 Million |
₩14.69 Billion ≈ $9.96 Million |
0.123x | +351.33% |
| 2023-12-31 | ₩106.99 Billion ≈ $72.51 Million |
₩2.91 Billion ≈ $1.97 Million |
0.027x | +173.37% |
| 2022-12-31 | ₩99.94 Billion ≈ $67.73 Million |
₩-3.70 Billion ≈ $-2.51 Million |
-0.037x | -150.21% |
| 2021-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩6.93 Billion ≈ $4.69 Million |
0.074x | +191.29% |
| 2020-12-31 | ₩95.14 Billion ≈ $64.48 Million |
₩-7.69 Billion ≈ $-5.21 Million |
-0.081x | -420.83% |
| 2019-12-31 | ₩98.58 Billion ≈ $66.81 Million |
₩2.48 Billion ≈ $1.68 Million |
0.025x | -51.59% |
| 2018-12-31 | ₩103.35 Billion ≈ $70.04 Million |
₩5.38 Billion ≈ $3.65 Million |
0.052x | -2.44% |
| 2017-12-31 | ₩102.19 Billion ≈ $69.26 Million |
₩5.45 Billion ≈ $3.69 Million |
0.053x | +272.82% |
| 2016-12-31 | ₩101.18 Billion ≈ $68.57 Million |
₩1.45 Billion ≈ $981.14K |
0.014x | -89.06% |
| 2015-12-31 | ₩97.20 Billion ≈ $65.87 Million |
₩12.71 Billion ≈ $8.61 Million |
0.131x | +18.32% |
| 2014-12-31 | ₩92.06 Billion ≈ $62.39 Million |
₩10.17 Billion ≈ $6.89 Million |
0.110x | -- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.